HC Wainwright Upgrades Upstream Bio (NASDAQ:UPB) to “Strong-Buy”

Upstream Bio (NASDAQ:UPB) was upgraded by analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

UPB has been the subject of several other research reports. Mizuho decreased their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Wall Street Zen cut Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings cut Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Finally, Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target for the company. in a report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Upstream Bio has an average rating of “Moderate Buy” and an average target price of $38.20.

Upstream Bio Stock Up 5.2%

Shares of NASDAQ:UPB opened at $7.63 on Wednesday. The business has a 50 day moving average price of $9.12 and a 200 day moving average price of $17.70. Upstream Bio has a twelve month low of $7.18 and a twelve month high of $33.68. The company has a market cap of $415.22 million, a price-to-earnings ratio of -2.62 and a beta of 1.10.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Analysts anticipate that Upstream Bio will post -2.99 EPS for the current year.

Institutional Investors Weigh In On Upstream Bio

Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in Upstream Bio during the 4th quarter worth approximately $29,000. Torren Management LLC bought a new position in Upstream Bio in the 4th quarter valued at $30,000. BNP Paribas Financial Markets boosted its position in Upstream Bio by 229.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after buying an additional 2,158 shares during the last quarter. Legal & General Group Plc boosted its position in Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after buying an additional 1,440 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Upstream Bio in the 4th quarter valued at $45,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.